Article thumbnail

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma

By Mark J. Hamblin and Maureen R. Horton


Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid arthritis (RA) contributing to significantly increased morbidity and mortality. Diagnosis can be challenging since patients are unlikely to report dyspnea due to an overall decrease in physical activity with advanced arthritic symptoms. Additionally, infections, drug toxicity, and environmental toxins can mimic ILD, creating significant diagnostic dilemmas for the clinician. In this paper we will explore an effective clinical algorithm for the diagnosis of RA-ILD. We will also discuss features of drug-related toxicities, infections, and environmental toxins that comprise the main entities in the differential diagnosis of RA-ILD. Finally, we will explore the known and experimental treatment options that may have some benefit in the treatment of RA-ILD

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1990). a a r t e n s ,P .A .W i l l c o x ,a n dS .R .B e n a t a r ,“ M i l i a r y tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults,”
  2. (2005). a m b o t t e ,R .K o t b ,G .M a i g n e ,F .X .B l a n c ,C .G o u j a r d
  3. (2004). a n a k a ,J .S .K i m ,J .D .N e w e l le ta l . ,“ R h e u m a t o i d arthritis-related lung diseases:
  4. (2004). a n s e y ,A .U .W e l l s ,T .V .C o l b ye ta l . ,“ V a r i a t i o n si n histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis,” Histopathology,
  5. (2009). a w a d a ,S .I n o k u m a ,T .S a t oe ta l . ,“ L e fl u n o m i d e - i n d u c e d interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis,”
  6. (2009). Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases,”
  7. (2007). Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis,”
  8. (2007). Acute exacerbations of idiopathic pulmonary fibrosis,”
  9. (1981). Adverse reactions affecting the lung: possible association with D-penicillamine,”
  10. (1979). Airways obstruction inrheumatoidarthritis,”Annals of theRheumatic Diseases,
  11. (1997). Alarc´ o n ,J .M .K r e m e r ,M .M a c a l u s oe ta l . ,“ R i s k factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study,”
  12. (2002). and the European Respiratory Society (ERS), “American thoracic society/European respiratory society internationalmultidisciplinary consensus classification of the idiopathic interstitial pneumonias,”
  13. (2005). Anticoagulant therapy for idiopathic pulmonary fibrosis,”
  14. (1998). B j o r a k e r ,J .H .R y u ,M .K .E d w i ne ta l . ,“ P r o g n o s t i c significance of histopathologic subsets in idiopathic pulmonary fibrosis,”
  15. (1996). Bronchiolar disease in rheumatoid arthritis,”
  16. (2005). BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment,”
  17. (1994). c D o n a g h ,M .G r e a v e s ,A .R .W r i g h t ,C .H e y c o c k
  18. (2008). c h i ,T .K u b o t a ,T .S u g i h a r ae ta l . ,“ Ac a s er e p o r t of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiple bullae and pneumomediastinum, which was successfully treated with tacrolimus,”
  19. (1999). C.Turesson,L.Jacobsson,andU.Bergstr¨ om,“Extra-articular rheumatoid arthritis: prevalence and mortality,”
  20. (2001). Cigarette smoking and rheumatoid arthritis,”
  21. Clinical and radiologic manifestations of hypersensitivity pneumonitis,”
  22. (2009). Clinical expression of leflunomide-induced pneumonitis,”
  23. (2004). Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis,”
  24. (2000). Cryptogenic organizing pneumonia: characteristics of relapses in a series of 48 patients,”
  25. (2001). D a w s o n ,H .E .F e w i n s ,J .D e s m o n d ,M .P .L y n c h
  26. (1995). D a y t o n ,D .A .S c h w a r t z ,N .L .S p r i n c ee ta l . ,“ L o w -dose methotrexate may cause air trapping in patients with rheumatoid arthritis,”
  27. (1996). Dalhoff,S .B a u e r f e i n d ,J .B a r t h ,a n dW
  28. (1976). Diffuse alveolitis as complication of penicillamine treatment for rheumatoid arthritis,”
  29. (1997). e g r e ,N .P u g n e r e ,M .T .A n t o n i n ie ta l . ,“ A i r w a y obstruction and rheumatoid arthritis,”
  30. (1980). e r v a n t e s - P e r e z ,A .H .T o r o - P e r e z ,a n dP .R o d r i g u e z -Jurado, “Pulmonary involvement in rheumatoid arthritis,”
  31. (2004). Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab,”
  32. (1995). G o l d e n ,R .S .K a t z ,R .A .B a l k ,a n dH .E .G o l d e n ,“ T h e relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis,”
  33. (2003). G´ o m e z - R e i n o ,L .C a r m o n a ,V .R o d r ´ ıguez
  34. (1997). Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease,”
  35. (1996). Guidelines for monitoring drug therapy in rheumatoid arthritis:
  36. (2005). Histopathologic pattern andclinical features of rheumatoid arthritis-associatedinterstitial lung disease,”
  37. Hypersensitivity pneumonitis,” Critical Reviews
  38. (2004). Hypersensitivity pneumonitis: a multifaceted deceiving disorder,”
  39. (1994). Idiopathic interstitial pneumonia that responded to intermittent intravenous administration of high-dose cyclophosphamide,”
  40. (2008). Idiopathic nonspecific interstitial pneumonia: report of an
  41. (1962). Incidence of laryngeal involvement in rheumatoid arthritis,”
  42. (1994). Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate,”
  43. (2010). Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register,” Annals of the Rheumatic Diseases,
  44. (2006). Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years,”
  45. (1997). Interstitial lung disease in recent onset rheumatoid arthritis,”
  46. (1993). Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography,”
  47. (2002). Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests,”
  48. (1996). Koehnke et al., “Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities,”
  49. (2008). l e x i o u ,A .G e r m e n i s ,A .K o u t r o u m p a s ,A .K o n t o g i a n n i
  50. (1997). laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review,”
  51. (2006). Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis,”
  52. (2003). Lynch III, “Bronchiolar complications of connective tissue diseases,”
  53. (1997). M a n g a n e l l i ,M .C a r o t t i ,S .S u b i a c o ,G .L a m a n n a
  54. (1996). M o r r i s o n ,G .M .M o d y ,S .R .B e n a t a r ,a n dO .L . Meyers, “The lungs in rheumatoid arthritis—a clinical, radiographic and pulmonary function study,”
  55. (2009). Mechanisms of activity-related dyspnea in pulmonary diseases,”
  56. (1996). Menk` es, “Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis,”
  57. (2000). Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients,”
  58. (2006). Methotrexateinduced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease,”
  59. (2006). Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia,”
  60. (2006). Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease,”
  61. Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamideto corticosteroids,”
  62. (1992). Nonsteroidal antiinflammatory drug-associated pulmonary infiltrates with eosinophilia: review of the literature and Food and Drug Administration Adverse Drug Reaction reports,”
  63. (2007). o p a ,M .J .L e a n d r o ,G .C a m b r i d g e ,a n dJ .C .W .E d w a r d s , “Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs,” Rheumatology,v o l .4 6 ,n o
  64. (1994). Obana et al., “Cause of death in 81 autopsied patients with rheumatoid arthritis,”
  65. (2007). P a r k ,D .K .K i m ,D .S .K i me ta l . ,“ M o r t a l i t ya n dr i s k factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia,”
  66. P a r k ,D .S .K i m ,I .N .P a r ke ta l . ,“ P r o g n o s i so ffi b r o t i c interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes,”
  67. (2007). P a r k ,D .S .K i m ,T .S .S h i me ta l . ,“ A c u t ee x a c e r b a t i o n of interstitial pneumonia other than idiopathic pulmonary fibrosis,”
  68. (2010). Papiris et al., “Clinical review: idiopathic pulmonary fibrosis acute exacerbations—unravelling
  69. (1996). Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy,”
  70. (2008). Progressive preclinical interstitial lung disease in rheumatoid arthritis,”
  71. (1987). Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy,”
  72. (1996). Pulmonary function in patients receiving longterm low-dose methotrexate,”
  73. (1996). Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study,”
  74. Pulmonary function measures predict mortality differently in idiopathic pulmonary fibrosis versus combined pulmonary fibrosis and emphysema,” European Respiratory Journal.
  75. (1998). Pulmonary toxicity of drugs used to treat systemic autoimmune diseases,”
  76. (2005). R.Buhlet al.,“High-doseacetylcysteine in idiopathic pulmonary fibrosis,” New England
  77. (2004). Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis,”
  78. (1995). Remy-Jardin et al., “Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis,”
  79. (1999). Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy,” Clinical and Experimental Rheumatology,
  80. (2004). Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction,”
  81. (2008). Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifi-brotic and disease-modifying antirheumatic drug,”
  82. (2009). Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern,”
  83. (2006). Rituximab for refractory Wegener’s granulomatosis: report of a prospective, openlabel pilot trial,”
  84. (2006). Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports,”
  85. (1981). Salicylate-induced pulmonary edema. Clinical features and prognosis,”
  86. (2001). Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis,”
  87. (2002). Successful use of immunosuppressive agents for the treatment of progressive rheumatoid interstitial lung disease: a case report,”
  88. (2008). T z e l e p i s ,S .P .T o y a ,a n dH .M .M o u t s o p o u l o s ,“ O c c u l t connective tissue diseases mimicking idiopathic interstitial pneumonias,”
  89. (1999). Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT10 Pulmonary Medicine patterns and their courses,”
  90. (2006). Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, diseasemodifying antirheumatic drugs, and anti-tumor necrosis factor therapy,”
  91. (1995). Treatment of progressive rheumatoid interstitial lung disease with cyclosporine,”
  92. (2005). V.Cottin,H.Nunes,P.Y.Brilletetal.,“Combinedpulmonary fibrosis and emphysema: a distinct underrecognised entity,”
  93. (2008). Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease,”
  94. (1968). W a l k e ra n dV .W r i g h t ,“ P u l m o n a r yl e s i o n sa n d rheumatoid arthritis,”
  95. (1998). W e y a n d ,D .S c h m i d t ,U .W a g n e r ,a n dJ .J .G o r o n z y , “The influence of sex on the phenotype of rheumatoid arthritis,”
  96. (2000). W.D.Travis,K.Matsui,J.Moss,andV.J.Ferrans,“Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns—survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia,”
  97. (2010). Z a p p a l a ,P .I .L a t s i ,A .G .N i c h o l s o ne ta l . ,“ M a r g i n a l decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis,”
  98. (2001). Z i s m a n ,W .J .M c C u n e ,G .T i n o ,a n dJ .P .L y n c h , “Drug-induced pneumonitis: the role of methotrexate,”